Highlights
- In demyelinating disease-associated uveitis, ultra-widefield fluorescein angiography (UWF-FA) may reveal persistent peripheral vascular leakage despite a clinically inactive examination and stable OCT.
- The 2026 American Journal of Ophthalmology cohort by Levant, Ray, and Venkat found angiographic-clinical discordance in nearly 70% of clinically inactive eyes, supporting the concept of subclinical retinal vasculopathy.
- These findings align biologically with the known retinal periphlebitis phenotype of multiple sclerosis (MS), but they do not yet establish that angiographic leakage alone should trigger treatment escalation.
- Prospective studies are needed to determine whether UWF-FA-defined activity predicts relapse, visual decline, structural damage, or neurologic disease burden, and whether it should become a therapeutic endpoint.
Background
Demyelinating disease-associated uveitis is an uncommon but clinically important intersection between neuroimmunology and ocular inflammation. Multiple sclerosis is the dominant associated demyelinating disorder, and the best-characterized ocular inflammatory phenotype is intermediate uveitis, often accompanied by vitreous inflammation, retinal venous sheathing, or peripheral retinal vasculitis. Historically, the ophthalmic literature has emphasized pars planitis-like inflammation and retinal periphlebitis in MS, while neurologic literature has viewed retinal vascular inflammation as part of a broader CNS inflammatory diathesis.
Routine monitoring of uveitis typically relies on slit-lamp examination, vitreous haze or cell grading, indirect ophthalmoscopy, and macular OCT for edema detection. These tools are clinically practical and codified by the Standardization of Uveitis Nomenclature (SUN) framework. However, they incompletely visualize the far peripheral retina, where vasculitic leakage may persist even after central signs improve. The increasing availability of UWF-FA has expanded the field of view sufficiently to detect peripheral capillary leakage, vessel wall staining, and nonperfusion that may be invisible on conventional examination or standard angiography.
The key unanswered question is whether this additional angiographic signal matters. Does peripheral leakage merely document low-grade immunologic residue, or does it identify biologically active disease with implications for visual prognosis, treatment intensity, and longitudinal structural damage? The 2026 study by Levant and colleagues directly addresses this issue in demyelinating disease-associated uveitis and invites comparison with broader uveitis imaging literature.
Key Content
Clinical phenotype of demyelinating disease-associated uveitis
MS-associated uveitis is uncommon relative to idiopathic or HLA-B27-associated anterior uveitis, but it is a recognized entity in tertiary practice. Across older cohort studies and reviews, intermediate uveitis has been the most frequent presentation, often bilateral, recurrent, and more common in women, reflecting the epidemiology of MS itself. Retinal periphlebitis has long been described in MS, sometimes in the absence of visually significant anterior segment inflammation, reinforcing the concept that retinal vascular pathology may be an integral feature rather than a secondary bystander.
Several clinic-based series published over the past two decades have emphasized the bidirectional association between MS and intermediate uveitis: some patients with pars planitis later develop neurologic demyelination, whereas others with established MS develop ocular inflammation during the course of systemic disease. This association has practical consequences because treatment decisions are constrained by neurologic comorbidity. Most notably, tumor necrosis factor-alpha inhibitors are generally avoided in patients with demyelinating disease because of concerns regarding demyelination exacerbation, shifting steroid-sparing strategies toward antimetabolites, calcineurin inhibitors, or B-cell-directed therapy in selected cases.
Why angiography matters in this disease
The biologic rationale for angiography in demyelinating disease-associated uveitis is strong. Retinal venous sheathing and periphlebitis in MS reflect leukocyte trafficking, endothelial activation, and blood-retinal barrier disruption, processes that mirror inflammatory events elsewhere in the CNS. Fluorescein angiography can reveal dye leakage from venous segments and peripheral microvasculature before overt complications such as cystoid macular edema, neovascularization, or hemorrhage emerge.
Conventional imaging, however, has important blind spots. Clinical quiescence as defined by 0 anterior chamber cells, 0 vitreous cells, and absence of active fundus lesions may not exclude low-grade vascular leakage. Likewise, OCT is exquisitely sensitive for center-involving edema but is not a direct measure of peripheral vasculitic activity. UWF-FA therefore offers a complementary disease map: it can localize the burden of leakage, demonstrate whether activity is central or peripheral, and identify nonperfusion or ischemic consequences that may guide surveillance.
The Levant-Ray-Venkat 2026 study: design and core findings
Levant SD, Ray H, and Venkat A reported a retrospective cohort study from a tertiary referral center examining 58 eyes of 30 patients with confirmed demyelinating disease, predominantly MS, and concurrent uveitis. The study combined a cross-sectional analysis of paired clinical and angiographic encounters with a longitudinal analysis across three disease states: initial presentation, acute flare, and most recent follow-up.
The methodology is a strength. Clinical inflammation was graded using SUN-compatible examination measures, while OCT captured central subfield thickness and the presence of intraretinal fluid (IRF) or subretinal fluid (SRF). UWF-FA leakage was scored anatomically across Zones 1 through 3, permitting topographic analysis of leakage burden. Importantly, the authors used linear mixed models and generalized estimating equations to account for within-patient inter-eye correlation and repeated measures, a statistically appropriate approach in ophthalmic cohorts where both eyes may contribute data.
The longitudinal findings showed that conventional inflammatory markers improved after flare: anterior chamber inflammation and vitreous cell grade both decreased significantly, and OCT evidence of macular exudation also improved, with reductions in IRF and SRF. By contrast, total angiographic leakage burden was greatest at presentation but did not significantly change between acute flare and the most recent encounter. The most provocative observation was the degree of clinical-angiographic discordance: among 48 paired encounters, 68.8% of eyes deemed clinically inactive still demonstrated ongoing vascular leakage on UWF-FA.
At the same time, the study did not show that far-peripheral Zone 3 leakage was a statistically significant predictor of concurrent IRF in multivariable analysis (odds ratio 2.33, 95% confidence interval 0.62-8.73; P = .21). This is an important nuance. Persistent peripheral leakage appears common, but its relationship to immediate macular fluid burden is not straightforward. Over time, however, cumulative structural damage including epiretinal membrane and macular atrophy increased significantly, raising the possibility that repeated inflammatory insults leave durable retinal sequelae even when conventional activity appears controlled.
How these findings fit with earlier literature on MS, retinal periphlebitis, and uveitis imaging
The study’s central premise is not entirely new; rather, it formalizes a suspicion present in the literature for decades. Earlier fluorescein angiographic studies in MS documented retinal periphlebitis and vascular leakage, often with a predilection for the peripheral venous circulation. Those studies were limited by narrower fields of view and less standardized grading, but they established that retinal vascular inflammation can outlast or exceed what is obvious on examination.
Broader uveitis imaging literature has similarly shown that UWF-FA frequently identifies peripheral vascular leakage not appreciated clinically. In noninfectious uveitis cohorts, peripheral angiographic abnormalities have altered management in a meaningful subset of patients by upgrading disease extent, clarifying the inflammatory phenotype, or prompting closer follow-up. Such findings are especially relevant in intermediate and posterior uveitis, where the disease burden often localizes outside the posterior pole.
What Levant and colleagues add is disease specificity. Demyelinating disease-associated uveitis has distinct therapeutic constraints and a known vascular phenotype, making the interpretation of peripheral leakage especially important. Their data suggest that the discordance between clinical quiescence and angiographic activity is not a generic imaging curiosity, but a frequent feature of this specific inflammatory subtype.
Mechanistic interpretation: what might subclinical leakage represent?
Several non-mutually exclusive mechanisms could explain persistent peripheral leakage in clinically inactive eyes.
First, it may reflect ongoing low-grade retinal vasculitis. Endothelial dysfunction and perivascular immune activation may persist after cellular inflammation in the aqueous and vitreous has normalized. In this model, leakage is a direct marker of active disease not captured by exam.
Second, it may represent delayed restoration of the blood-retinal barrier after an acute flare. Leakage could persist for weeks or months despite suppression of the immune trigger, analogous to radiographic lag in other inflammatory conditions. If so, UWF-FA may be more sensitive than specific for meaningful activity.
Third, structural vascular remodeling may contribute. Previously inflamed peripheral vessels may stain or leak because of residual wall damage even when the inflammatory process is largely quiescent. This possibility is clinically crucial because it would weaken the argument that every angiographic abnormality warrants treatment intensification.
Fourth, leakage may be biologically linked to systemic CNS inflammation. The retina is often described as a window to the brain, and retinal vascular inflammatory signatures in MS may track with broader neuroinflammatory processes. This remains speculative in uveitis cohorts, but it is an attractive translational hypothesis deserving prospective study with neurologic imaging and disability measures.
Clinical utility of UWF-FA: where it may help most
For practicing uveitis specialists, UWF-FA appears most useful in four settings.
Initial phenotyping. At first presentation, UWF-FA can define the full anatomic extent of vascular leakage, distinguish focal from diffuse peripheral involvement, identify concomitant nonperfusion, and establish a baseline for future comparison.
Explaining discordant symptoms or signs. Patients may report photopsias, blur, or fluctuating symptoms despite minimal central findings. Peripheral angiographic activity may clarify such cases.
Monitoring recurrent disease. In recurrent intermediate uveitis associated with MS, UWF-FA may detect ongoing vascular activity during apparent remission and help contextualize whether a patient’s course is smoldering rather than truly intermittent.
Complication surveillance. Persistent vasculitic leakage may coexist with ischemia, epiretinal membrane formation, or eventual macular structural changes. Identifying such eyes may justify closer OCT surveillance and more systematic follow-up.
That said, utility should not be conflated with actionability. The current evidence base is insufficient to conclude that treatment should be escalated solely on the basis of peripheral leakage in an asymptomatic eye with stable vision and no OCT edema.
Therapeutic implications and current limits
The Levant study naturally raises the question of therapeutic targets. Should remission in demyelinating disease-associated uveitis be defined clinically, structurally, or angiographically? At present, most treatment paradigms for noninfectious uveitis still prioritize symptoms, clinical inflammatory grade, visual function, and vision-threatening complications such as cystoid macular edema or retinal vascular occlusion. Angiography informs these decisions but is rarely the sole determinant.
This conservative stance is especially appropriate in MS-associated disease. Corticosteroid overexposure carries systemic and ocular toxicity. Steroid-sparing immunomodulators have delayed onset and monitoring burdens. Some biologic options are limited by demyelination concerns. Therefore, a more sensitive test that detects more abnormalities is not automatically beneficial unless acting on those findings improves patient-centered outcomes.
One plausible middle-ground approach is risk stratification rather than reflex escalation. For example, persistent Zone 3 leakage in a clinically quiet eye might prompt shorter follow-up intervals, repeat UWF-FA at a defined interval, or a lower threshold for therapy adjustment if structural complications emerge. Eyes with persistent leakage plus recurrent edema, progressive epiretinal membrane, or declining visual function may represent a higher-risk subgroup more likely to benefit from treatment intensification.
Methodological strengths and weaknesses of the new evidence
The 2026 cohort has several strengths: disease confirmation, paired multimodal imaging, topographic grading of leakage, and appropriate repeated-measures statistics. It also addresses an under-studied population rather than extrapolating from heterogeneous uveitis cohorts.
Its limitations are equally important. The sample size is modest, reflecting disease rarity but restricting precision, especially in multivariable modeling. As a retrospective tertiary-center cohort, referral bias likely enriched for more complex disease. Imaging timing relative to treatment changes was not randomized, so leakage persistence could reflect nonstandardized therapeutic windows. The absence of a validated, externally standardized UWF-FA activity scoring system for this specific condition also limits comparability. Most importantly, the study does not establish prognosis: it shows discordance, not that discordance predicts worse outcomes or that treating it changes outcomes.
These limitations should temper overinterpretation. The findings justify attention, not automatic practice change.
Guideline context and disease monitoring standards
The SUN Working Group provided the foundational framework for clinical inflammatory grading in uveitis, which remains essential for trial design and routine care. More recently, SUN has evolved toward machine-readable outcome measures and standardized endpoints, but angiographic remission is still not a universal requirement across uveitis subtypes. In parallel, ophthalmic imaging consensus documents increasingly recognize the value of multimodal imaging, especially OCT and fluorescein angiography, in posterior segment disease.
For demyelinating disease-associated uveitis specifically, no major guideline currently mandates serial UWF-FA in clinically quiescent patients. This is understandable given sparse prospective evidence. Nonetheless, the present study strengthens the argument that imaging protocols in this phenotype may need to be more deliberate than simple examination-plus-OCT strategies.
Translational implications and future research agenda
The most important next step is prospective validation. Several questions should be prioritized.
Does persistent UWF-FA leakage predict relapse? A longitudinal cohort with predefined imaging intervals could determine whether clinically quiet eyes with residual leakage relapse sooner than angiographically quiet eyes.
Does it predict cumulative structural injury? The observed increase in epiretinal membrane and macular atrophy suggests a chronic damage signal. Future studies should test whether baseline leakage burden correlates with later retinal thinning, ellipsoid zone disruption, or irreversible visual loss.
Does treatment guided by angiography improve outcomes? The decisive evidence would come from an imaging-guided management study comparing standard care versus care incorporating UWF-FA-defined activity. Endpoints should include visual acuity, edema recurrence, corticosteroid burden, quality of life, and adverse events.
Can angiography be integrated with biomarkers? Combining UWF-FA with OCT, OCT angiography, serum neurofilament light chain, or MRI metrics of CNS activity could clarify whether ocular vascular leakage is merely local or reflects systemic neuroinflammatory state.
Can scoring be standardized? A reproducible grading schema for peripheral leakage distribution and intensity would improve comparability across centers and support trial endpoints.
These studies are particularly feasible in collaborative neuro-ophthalmology and uveitis networks, where demyelinating disease-associated uveitis cases can be pooled to overcome sample-size limitations.
Expert Commentary
The central contribution of the Levant-Ray-Venkat study is conceptual: it challenges the assumption that examination-defined quiescence in demyelinating disease-associated uveitis equals complete inflammatory control. For clinicians accustomed to relying on SUN cell grades and macular OCT, the paper is a reminder that the retina’s far periphery may harbor residual vascular activity invisible to routine methods.
Still, this should not be interpreted as proof that current monitoring standards are inadequate in every patient. The study did not demonstrate a statistically significant relationship between far-peripheral leakage and concurrent IRF, and it did not show that angiographic abnormalities alone caused worse near-term visual outcomes. The increase in cumulative structural damage is concerning, but causality remains uncertain. Some damage may reflect past disease severity rather than ongoing subclinical activity.
From a mechanistic standpoint, the findings are plausible and compelling. MS is a perivenular inflammatory disease of the CNS; retinal venous leakage as a subclinical remnant of this biology makes sense. From a therapeutic standpoint, however, caution is warranted. More imaging often reveals more abnormalities, but medicine advances only when distinguishing actionable abnormalities from epiphenomena. The immediate value of UWF-FA may therefore lie less in triggering treatment escalation and more in improved phenotyping, risk stratification, and more accurate disease staging.
My practical interpretation is as follows: in patients with demyelinating disease-associated uveitis, especially those with recurrent intermediate uveitis, venous sheathing, unexplained symptoms, prior macular edema, or structural damage accrual, UWF-FA is a high-yield adjunct. In contrast, routine serial angiography in every asymptomatic patient with stable vision may be premature until prognostic and interventional data mature.
Conclusion
Subclinical peripheral vascular leakage appears to be a frequent feature of demyelinating disease-associated uveitis when assessed with UWF-FA. The 2026 study by Levant and colleagues provides important disease-specific evidence that clinical examination and OCT may underestimate the extent of residual retinal vascular abnormality, with nearly seven in ten clinically inactive eyes still showing angiographic leakage.
The study does not yet justify redefining treatment endpoints around angiographic remission alone, but it meaningfully expands the monitoring conversation. For now, UWF-FA should be viewed as a complementary tool that refines phenotyping and may identify patients with smoldering vasculitic activity or higher cumulative damage risk. Future prospective, imaging-guided studies will determine whether this angiographic signal is simply detectable or truly clinically decisive.
References
- Levant SD, Ray H, Venkat A. Subclinical Peripheral Vascular Leakage in Demyelinating Disease-Associated Uveitis. Am J Ophthalmol. 2026. PMID: 42235728.
- Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005.
- Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004.
- Engelhard SB, Patel V, Reddy AK. Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic United States. Clin Ophthalmol. 2015.
- Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T, Huong DL, Piette JC, LeHoang P. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001.
- Le Scanff J, Sève P, Renoux C, Broussolle C, Confavreux C, Vukusic S. Uveitis associated with multiple sclerosis. Mult Scler. 2008.
- Lightman S, Tomkins-Netzer O. The place of ultra-widefield imaging in the management of non-infectious posterior uveitis. Int Ophthalmol. 2019.
- Campbell JP, Leder HA, Sepah YJ, Gan T, Dunn JP, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, Do DV, Nguyen QD. Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol. 2012.
- Nicholson BP, Nigam D, Miller D, Agrón E, Dalal M, Nussenblatt RB, Sen HN. Fundus fluorescein angiography versus ocular clinical examination in guiding management of noninfectious intermediate, posterior, and panuveitis. Ophthalmology. 2014.
- Shulman S, Goldenberg D, Habot-Wilner Z. Imaging in uveitis: current applications and future directions. Int Ophthalmol Clin. 2015.